Company
Pharma Mar, SA
Headquarters: Madrid, Spain
Employees: 477
CEO: Mr. Jose Maria Fernandez Sousa-Faro
Market Cap
€1.44 Billion
EUR as of July 1, 2025
US$1.71 Billion
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | €175.7 M |
| EBITDA | €21.0 M |
| Gross Profit TTM | €165.9 M |
| Profit Margin | 11.31% |
| Operating Margin | -7.94% |
| Quarterly Revenue Growth | 2.30% |
Stocks & Indices
Pharma Mar, SA has the following listings and related stock indices.
Stock: BME: PHM wb_incandescent
Stock: FSX: PMRA wb_incandescent
Stock: OTC: PHMMF wb_incandescent